|
|
|
Insider
Information: |
Siffert Joao Md |
Relationship: |
President and CEO, Dir... |
City: |
Aliso Viejo |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
4 |
|
Direct
Shares |
546,811 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$19,160 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
546,811 |
|
|
Total
Value |
$19,160 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Avanir Pharmaceuticals |
AVNR |
SVP, R&D |
2014-12-18 |
314,192 |
2011-12-15 |
0 |
Premium* |
|
Avexis, Inc. |
AVXS |
Director |
2018-05-15 |
0 |
2018-03-13 |
0 |
Premium* |
|
Abeona Therapeutics Inc |
ABEO |
Chief Executive Office... |
2020-05-20 |
100,000 |
2020-05-20 |
0 |
Premium* |
|
Design Therapeutics, Inc. |
DSGN |
President and CEO, Dir... |
2022-12-20 |
132,619 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
20 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
DSGN |
Design Therapeutics, Inc. |
President and CEOOfficer |
|
2021-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
122,699 |
|
- |
|
DSGN |
Design Therapeutics, Inc. |
President and CEO |
|
2022-12-19 |
4 |
B |
$8.47 |
$9,741 |
D/D |
1,150 |
126,319 |
2.81 |
- |
|
DSGN |
Design Therapeutics, Inc. |
President and CEO |
|
2022-12-20 |
4 |
B |
$8.38 |
$52,763 |
D/D |
6,300 |
132,619 |
2.81 |
- |
|
AVXS |
Avexis, Inc. |
Director |
|
2018-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,106 |
1,106 |
0 |
- |
|
AVXS |
Avexis, Inc. |
Director |
|
2018-05-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,106) |
0 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2011-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
29,500 |
29,500 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2012-05-10 |
4 |
B |
$2.96 |
$7,992 |
D/D |
2,700 |
32,200 |
2.74 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2012-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
84,000 |
116,200 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2013-09-18 |
4 |
AS |
$4.22 |
$88,968 |
D/D |
(21,094) |
116,200 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2013-09-18 |
4 |
OE |
$1.85 |
$39,024 |
D/D |
21,094 |
137,294 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2013-12-18 |
4 |
AS |
$2.63 |
$15,713 |
D/D |
(5,970) |
110,230 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2014-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
123,750 |
233,980 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2014-05-28 |
4 |
S |
$5.18 |
$70,173 |
D/D |
(13,547) |
230,980 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2014-10-24 |
4 |
AS |
$11.80 |
$99,427 |
D/D |
(8,426) |
222,554 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2014-11-10 |
4 |
A |
$0.00 |
$0 |
D/D |
34,825 |
316,610 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2014-11-10 |
4 |
A |
$0.00 |
$0 |
D/D |
59,231 |
281,785 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2014-12-18 |
4 |
AS |
$16.93 |
$262,500 |
D/D |
(15,505) |
314,192 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2014-12-18 |
4 |
D |
$16.99 |
$326,276 |
D/D |
(19,204) |
329,697 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
SVP, R&D |
|
2014-12-18 |
4 |
OE |
$2.59 |
$83,634 |
D/D |
32,291 |
348,901 |
0 |
- |
|
ABEO |
Abeona Therapeutics Inc |
Chief Executive Officer |
|
2020-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
0 |
- |
|
20 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|